Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $5.63

Key Points

• Vor Biopharma Inc. (NYSE:VOR) has received a consensus rating of "Moderate Buy" from ten rating firms, with four analysts recommending a hold and six advising a buy.
• The average 12-month target price for VOR among brokerages is $5.63, reflecting a positive outlook despite recent fluctuations in analyst ratings.
• The company operates as a clinical-stage cell and genome engineering firm, with its lead product, tremtelectogene empogeditemcel, currently in phase 1/2 trials for treating acute myeloid leukemia.

Shares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have earned an average rating of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $5.63.

A number of equities research analysts have weighed in on VOR shares. Citizens Jmp lowered Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 9th. HC Wainwright raised Vor Biopharma from a "neutral" rating to a "buy" rating and set a $3.00 target price for the company in a research report on Monday, June 30th. Jones Trading lowered Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. JMP Securities reaffirmed a "market perform" rating and set a $6.00 target price on shares of Vor Biopharma in a research report on Friday, May 9th. Finally, Baird R W lowered Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VOR. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in Vor Biopharma during the 4th quarter valued at approximately $33,000. Money Concepts Capital Corp raised its position in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after buying an additional 26,535 shares during the last quarter. Virtu Financial LLC purchased a new position in Vor Biopharma during the 4th quarter worth approximately $60,000. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after buying an additional 58,247 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Vor Biopharma during the 4th quarter worth approximately $80,000. Institutional investors and hedge funds own 97.29% of the company's stock.

Vor Biopharma Stock Performance

VOR stock traded up $0.03 during midday trading on Wednesday, reaching $2.10. The company's stock had a trading volume of 2,451,634 shares, compared to its average volume of 8,204,835. The stock has a fifty day simple moving average of $1.18 and a two-hundred day simple moving average of $0.99. Vor Biopharma has a 1 year low of $0.13 and a 1 year high of $3.29. The firm has a market capitalization of $262.42 million, a price-to-earnings ratio of -1.27 and a beta of 2.04.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.